Astellas plans to invest over €330m in new facility in Ireland

Betsy Goodfellow | September 18, 2023 | News story | Manufacturing and Production Astellas Pharma, Ireland, Pharmacy, facility, manufacturing 

Astellas Pharma has announced that it is preparing to submit a planning application to build a new state-of-the-art facility at an estimated cost of €330m in Tralee, County Kerry, Ireland.

The investment is intended to expand the company’s capacity and capabilities for aseptic drug products, as well as reinforcing stable production for global supply and accelerating the development and commercialisation of new antibody drugs and other new products.

The new facility is intended to be based on the Industrial Development Authority’s (IDA) greenfield site in Kerry Technology Park, Tralee.

Hideki Shima, chief manufacturing officer at Astellas commented: “Astellas is developing innovative drugs and technologies based on our Focus Area research and development approach, placing patients at the forefront of everything we do. With the new facility, Astellas will aim to strengthen our in-house production capacity and capabilities and ensure a stable supply of high-quality Astellas medicines to patients around the world.”

Michael Lohan, CEO at IDA, added: “This announcement from Astellas is excellent news for the South West region and indeed Ireland. Astellas already has a presence in both Kerry and Dublin and this significant investment of approximately €330m, adding a new state-of-the-art aseptic drug product facility, underscores the strategic importance Ireland plays in Astellas’ global operations. The new facility in Tralee will be built with sustainability at its core and will showcase Ireland and our regional attractiveness as a location for investment.”

Betsy Goodfellow

Related Content

Astellas set to open new life sciences facilities in Cambridge, Massachusetts

On 9 August 2023, Astellas Pharma announced its plans to open what it has described …


Astellas announces FDA approval for Izervay for GA treatment

Astellas Pharma has announced that the US Food and Drug Administration (FDA) has approved Izervay …

Pharma pill manufacturing

Biovian announces investment in manufacturing facility in Finland

Biopharmaceutical based contract development and manufacturing organisation (CDMO) Biovian OY has announced an investment of …

Latest content